Drug Shortage Report for TEVA-LANSOPRAZOLE
Report ID | 88177 |
Drug Identification Number | 02280515 |
Brand name | TEVA-LANSOPRAZOLE |
Common or Proper name | LANSOPRAZOLE |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | LANSOPRAZOLE |
Strength(s) | 15MG |
Dosage form(s) | CAPSULE (DELAYED RELEASE) |
Route of administration | ORAL |
Packaging size | 100 |
ATC code | A02BC |
ATC description | DRUGS FOR PEPTIC ULCER AND GASTROESOPHAGEAL REFLUX DISEASE (GERD) |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2019-06-30 |
Estimated end date | |
Actual end date | 2021-01-26 |
Shortage status | Resolved |
Updated date | 2021-01-28 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2019-07-02 | English | Compare |
v2 | 2019-07-02 | French | Compare |
v3 | 2021-01-28 | English | Compare |
v4 | 2021-01-28 | French | Compare |
Showing 1 to 4 of 4